The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

On February 28, Praxis shared the results of a pre-planned interim analysis of Study 1. The Independent Data Monitoring ...

Despite these benefits, biosimilar medicines remain under-recognised and underused in many markets. Real-world uptake often ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's ...

The European Medicines Agency’s (EMA)) human medicines committee (CHMP) has recommended seven novel medicines for approval at ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

today announced that the European Commission (EC) has granted orphan drug designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD). DYNE-251 is being evaluated in the Phase ...

"The strong global launch of YORVIPATH positions 2025 to be an inflection point for Ascendis with growing revenue and a path ...

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.